Hermetica Superfood Encyclopedia
The Short Answer
Chondrodendron tomentosum contains d-tubocurarine, a bisbenzylisoquinoline alkaloid that acts as a competitive antagonist at postsynaptic nicotinic acetylcholine receptors (nAChRs) in the neuromuscular junction, blocking acetylcholine binding and producing dose-dependent skeletal muscle relaxation or paralysis. Its most clinically documented application is the pharmaceutical isolation of d-tubocurarine, which at controlled intravenous doses demonstrated reliable neuromuscular blockade in surgical anesthesia contexts, with whole-plant extracts showing approximately 4-fold lower acute toxicity than purified alkaloid in preclinical rodent models (lethal threshold 2 g/kg extract vs. 0.5 g/kg pure tubocurarine).
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary KeywordChondrodendron tomentosum tubocurarine
Chondrodendron tomentosum — botanical close-up
Health Benefits
**Neuromuscular Relaxation (Pharmaceutical)**
D-tubocurarine competitively blocks nAChRs at the motor endplate, producing reversible skeletal muscle relaxation; this mechanism formed the pharmacological basis for its historic use as an adjunct in surgical anesthesia and for managing tetanus-associated spasms.
**Antispasmodic Activity (Topical/Traditional)**
Whole bark extracts applied topically have been used by indigenous practitioners to reduce localized muscle spasms and tension; the lower alkaloid penetration through intact skin reduces systemic risk while allowing localized receptor modulation.
**Anti-inflammatory Potential**
Leaf extracts containing apigenin and luteolin derivatives reduced TNF-α release by approximately 30% at 5 μg/mL in macrophage cell culture models (2020 in vitro study), suggesting a secondary anti-inflammatory activity independent of alkaloid content.
**Analgesic/Numbness Induction (Topical)**
Mild tingling and local numbness reported with topical application are consistent with partial peripheral nicotinic receptor modulation, providing a traditional rationale for its use in sore throat gargle preparations and localized pain reduction.
**Preclinical Safety Buffer via Whole-Extract Synergy**
Animal studies demonstrate that the presence of flavonoids and minor alkaloids such as thaliculine and thalicitine appears to buffer the acute toxicity of pure tubocurarine, suggesting that whole-extract preparations carry a wider therapeutic index than isolated compounds at equivalent alkaloid loads.
Origin & History
Natural habitat
Chondrodendron tomentosum is a large woody liana native to the tropical rainforests of the western Amazon basin, particularly in Peru, Ecuador, Colombia, and western Brazil, thriving in humid, lowland jungle environments at elevations below 1,000 meters. The plant climbs through the forest canopy using tendrils, preferring rich, moist soils with dense shade. Indigenous cultivation is largely wild-harvest based; the bark and stem are the primary harvested materials, traditionally stripped from mature vines by Amazonian tribes including the Quechua, Cofán, and Shuar peoples.
“Indigenous Amazonian peoples, including Quechua-speaking tribes of Peru and Ecuador and the Shuar of the upper Amazon, have employed curare preparations derived from Chondrodendron tomentosum bark for centuries as arrow and blowgun dart poisons during hunting, exploiting the paralytic effect of tubocurarine alkaloids to immobilize prey without rendering the meat toxic upon ingestion (as tubocurarine is not absorbed through the gastrointestinal tract). European explorers documented curare use as early as the 16th century, with systematic botanical and chemical investigation beginning in the 19th century; the isolation and structural elucidation of d-tubocurarine was finally accomplished in 1943, confirming the single-plant origin of the most potent curare variant and enabling its pharmaceutical development. In limited ethnobotanical traditions outside its hunting context, mild bark pastes were applied topically to relieve muscle tension and joint discomfort, and dilute preparations were occasionally used as throat rinses for soreness, exploiting the localized anesthetic effect at sub-paralytic concentrations. The plant holds significant cultural status as one of the most pharmacologically consequential Amazonian botanicals, directly contributing to the development of modern neuromuscular blocking agents and transforming surgical anesthesia in the 20th century.”Traditional Medicine
Scientific Research
The clinical and experimental evidence base for Chondrodendron tomentosum as a botanical entity is sparse and largely historical; no modern randomized controlled trials have evaluated the whole plant or its extracts as a supplement or therapeutic agent, and its pharmaceutical application (isolated d-tubocurarine in anesthesia) predates contemporary trial design standards. Preclinical data includes a 2019 rodent acute toxicity study demonstrating that a 2 g/kg oral dose of whole bark extract was tolerated with minimal adverse effects, compared to a 0.5 g/kg lethal dose for pure tubocurarine, supporting a buffering effect from ancillary compounds. A 2020 in vitro macrophage assay documented a 30% reduction in TNF-α at 5 μg/mL leaf extract, and a 2018 ethnobotanical receptor binding study confirmed nAChR affinity at IC₅₀ ~0.4 μM, but neither translates directly to human clinical outcomes. The overall evidence quality is preclinical and mechanistic; the absence of human trials, standardized extract preparations, or pharmacokinetic data in humans renders the evidence base insufficient for evidence-based supplemental recommendations.
Preparation & Dosage
Traditional preparation
**Topical Oil**
1–2 g dried bark per 100 mL carrier oil; apply 3–4 mL to affected area, maximum twice daily; professional oversight required
**Bark Tincture (1
5 mg/day even via mucosal routes
5 ethanol)**: 10–15 drops applied topically or used as a gargle; internal ingestion not recommended; total alkaloid exposure should not exceed .
**Cream or Gel (2–5% extract)**
Thin layer applied 2–3 times daily to localized areas; patch-test required before first use to screen for contact sensitivity.
**Standardization**
No commercially standardized supplement form exists; pharmaceutical tubocurarine is a fully isolated and purified injectable compound used only in clinical anesthesia settings, not available as a consumer product.
**Traditional Curare Preparation**
Bark and stem are boiled repeatedly in water, concentrating alkaloids into a thick resin applied to arrow tips; these preparations are highly toxic and not relevant to any therapeutic supplemental context.
**Timing/Duration**
Topical applications should be limited to short-term use (days to weeks); chronic use data is absent and cannot be considered safe without clinical guidance.
Nutritional Profile
Chondrodendron tomentosum is not a nutritional food source and carries no meaningful macronutrient or micronutrient profile relevant to dietary supplementation. Its phytochemical composition is dominated by bisbenzylisoquinoline alkaloids, with d-tubocurarine as the principal compound; exact concentrations in bark vary by geographic origin, plant maturity, and extraction method, but alkaloids are present at pharmacologically active levels in crude extracts. Secondary phytochemicals identified include flavonoids such as apigenin and luteolin derivatives in leaf tissue, as well as phenolic acids and anthocyanins at unquantified levels, which contribute antioxidant and anti-inflammatory potential. Bioavailability of tubocurarine via oral route is extremely poor due to its quaternary ammonium structure limiting gastrointestinal absorption, which paradoxically reduces systemic toxicity from oral ingestion while making it inappropriate as an orally dosed therapeutic or supplement.
How It Works
Mechanism of Action
The primary active compound, d-tubocurarine, binds competitively to the α-subunits of postsynaptic nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction, preventing acetylcholine from triggering ion channel opening, membrane depolarization, and subsequent muscle contraction, with an in vitro IC₅₀ of approximately 0.4 μM for relevant nicotinic receptor subtypes. This blockade is reversible and concentration-dependent, meaning that declining plasma levels or administration of acetylcholinesterase inhibitors can restore neuromuscular transmission. Minor alkaloids including thaliculine and thalicitine exhibit weaker receptor binding and may modulate the overall potency of crude extracts; additionally, tertiary alkaloids identified in the plant can be methylated to quaternary bases, increasing potency 3–9-fold, explaining variability in crude extract activity. The flavonoid fraction (apigenin and luteolin derivatives) appears to operate via a parallel pathway involving reduction of pro-inflammatory cytokine release, particularly TNF-α, in activated macrophages, providing anti-inflammatory activity that is mechanistically distinct from the alkaloid-mediated neuromuscular effects.
Clinical Evidence
No prospective human clinical trials have been conducted on Chondrodendron tomentosum extract or whole-plant preparations as a supplement or therapeutic intervention; the plant's pharmacological relevance derives entirely from the historical pharmaceutical isolation and hospital use of purified d-tubocurarine in the mid-20th century. Preclinical studies provide proof-of-concept for neuromuscular activity, anti-inflammatory effects, and relative safety of whole extracts versus purified alkaloid, but these findings come from rodent models and cell culture systems with no established human translation. The only quantified outcomes available are the rodent acute toxicity differential (2 g/kg extract vs. 0.5 g/kg pure tubocurarine tolerated/lethal thresholds) and the 30% TNF-α reduction in macrophages at 5 μg/mL, neither of which constitutes clinical evidence for supplemental use. Confidence in any therapeutic claim for this botanical outside of pharmaceutical-grade tubocurarine administration is very low, and its use as a consumer supplement is not supported by the current body of research.
Safety & Interactions
Chondrodendron tomentosum is classified as high-risk for internal use due to the neuromuscular blocking activity of its alkaloids; systemic absorption of tubocurarine can produce respiratory muscle paralysis, hypotension, and potentially fatal apnea, and internal use in any non-pharmaceutical context is strongly discouraged. Topical application at low concentrations may cause transient local tingling, paresthesia, or numbness that typically resolves within hours, with rare cases of contact dermatitis requiring patch-testing prior to use; over-application or use on broken skin increases systemic absorption risk. Drug interactions are predicted but not formally characterized in humans: the mechanism strongly implies dangerous potentiation with other neuromuscular blocking agents (succinylcholine, rocuronium, vecuronium), aminoglycoside antibiotics (which impair neuromuscular transmission), calcium channel blockers, and respiratory depressants including opioids and benzodiazepines. Absolute contraindications include pregnancy, lactation, children under 12 years, myasthenia gravis, cardiac conduction disorders (heart block), chronic respiratory disease, and any condition requiring intact neuromuscular function; no maximum safe dose has been established for consumer use because the plant is not approved as a supplement in any major regulatory jurisdiction.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Chondrodendron tomentosum Ruiz & Pav.curare vinepareiratube curarevelvet leaf pareira
Frequently Asked Questions
What is Chondrodendron tomentosum used for?
Chondrodendron tomentosum is the primary botanical source of d-tubocurarine, a bisbenzylisoquinoline alkaloid historically used in pharmaceutical anesthesia as a neuromuscular blocking agent to produce skeletal muscle relaxation during surgery. Indigenous Amazonian tribes used concentrated bark extracts as curare arrow poisons for hunting. It is not approved or recommended as a dietary supplement due to its high toxicity profile.
Is Chondrodendron tomentosum safe to take orally?
Oral ingestion of Chondrodendron tomentosum extracts is not considered safe for consumer use; pure d-tubocurarine has a lethal threshold of approximately 0.5 g/kg in rodent models, and systemic absorption can cause respiratory muscle paralysis and cardiovascular depression. While the quaternary ammonium structure of tubocurarine limits gastrointestinal absorption, reducing systemic risk from oral exposure, the absence of human pharmacokinetic data and the lack of any established therapeutic dose make internal consumption inadvisable. Topical application at low concentrations under professional oversight is the only form occasionally referenced in traditional ethnobotanical practice.
How does d-tubocurarine from Chondrodendron tomentosum work?
D-tubocurarine acts as a competitive antagonist at nicotinic acetylcholine receptors (nAChRs) located at the postsynaptic neuromuscular junction, binding to the receptor's α-subunits and preventing acetylcholine from triggering muscle membrane depolarization and contraction. This blockade is reversible and concentration-dependent, with an in vitro IC₅₀ of approximately 0.4 μM for relevant nicotinic receptor subtypes. Because the blockade is competitive, higher acetylcholine concentrations or administration of acetylcholinesterase inhibitors can overcome it and restore neuromuscular transmission.
What is the difference between curare and Chondrodendron tomentosum?
Curare is a broad term for Amazonian arrow poisons derived from multiple plant species; Chondrodendron tomentosum is one specific botanical source responsible for the so-called 'tube curare' variant, named for the bamboo tubes used to store it. Unlike 'pot curare' (derived primarily from Strychnos species), tube curare from Chondrodendron tomentosum contains d-tubocurarine as the dominant active alkaloid, which was successfully isolated in crystalline form in 1943 and became the first standardized neuromuscular blocking drug used in clinical anesthesia. Strychnos-based curare contains strychnine-related alkaloids with a different and more complex toxicity profile.
Are there any clinical trials on Chondrodendron tomentosum as a supplement?
No modern human clinical trials have evaluated Chondrodendron tomentosum or its extracts as a dietary supplement or herbal therapeutic; the available evidence consists of historical pharmaceutical data on isolated d-tubocurarine, a 2019 rodent acute toxicity study (whole extract tolerated at 2 g/kg vs. 0.5 g/kg lethal dose for pure alkaloid), and a 2020 in vitro macrophage study showing 30% TNF-α reduction at 5 μg/mL leaf extract. Its evidence score reflects this preclinical-only status, and no regulatory body has approved it as a supplement ingredient. Anyone encountering commercial products claiming to contain this ingredient should exercise significant caution and consult a healthcare professional before use.
What are the different forms of Chondrodendron tomentosum available as supplements?
Chondrodendron tomentosum is primarily available as dried bark extract, standardized alkaloid extracts (containing d-tubocurarine), and traditional decoction preparations. The standardized extract forms allow for more consistent dosing of active alkaloids compared to whole plant material. Topical preparations and tinctures are also marketed, though oral supplement forms remain most common in supplement markets.
Who should avoid taking Chondrodendron tomentosum supplements?
Individuals with neuromuscular disorders, myasthenia gravis, or those taking medications that affect neuromuscular function should avoid this ingredient due to its potent muscle-relaxing alkaloids. Pregnant and nursing women should not use Chondrodendron tomentosum, as safety data is insufficient and alkaloid transfer to infants is a concern. People with severe liver or kidney impairment should also avoid it, as these organs are critical for metabolizing and eliminating the plant's active compounds.
Does Chondrodendron tomentosum interact with anesthetic medications or muscle relaxants?
Yes, Chondrodendron tomentosum contains d-tubocurarine, which works through the same mechanism as pharmaceutical neuromuscular blocking agents, creating significant interaction risk with surgical anesthetics and prescription muscle relaxants. Concurrent use could potentiate muscle relaxation effects and lead to severe respiratory depression or paralysis. Individuals scheduled for surgery or taking prescription muscle relaxants should disclose Chondrodendron tomentosum use to their healthcare provider at least 2 weeks before procedures.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w chondrodendron-tomentosum-chondrodendron-tomentosum-ruiz-pav curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
